Sanofi (NASDAQ:SNY) Shares Sold by First Bank & Trust

First Bank & Trust lowered its position in Sanofi (NASDAQ:SNY) by 3.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,964 shares of the company’s stock after selling 2,303 shares during the period. First Bank & Trust’s holdings in Sanofi were worth $2,747,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Abel Hall LLC grew its holdings in Sanofi by 1.8% during the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after buying an additional 194 shares during the last quarter. PDS Planning Inc grew its holdings in Sanofi by 3.1% during the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after buying an additional 200 shares during the last quarter. Eagle Ridge Investment Management grew its holdings in Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after buying an additional 203 shares during the last quarter. Financial Advocates Investment Management grew its holdings in Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after buying an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC grew its holdings in Sanofi by 1.9% during the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after buying an additional 210 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Trading Down 0.6 %

Shares of SNY opened at $53.60 on Thursday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $136.03 billion, a P/E ratio of 21.53, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The stock’s fifty day simple moving average is $50.65 and its 200 day simple moving average is $52.49. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.